High-dose Tigecycline may potentially lead to a shorter treatment duration for certain bacterial infections, as suggested by a study published in the journal Antimicrobial Agents and Chemotherapy [1]. Tigecycline is a broad-spectrum antibiotic used to treat various infections, including complicated skin and soft tissue infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [2].

The study mentioned above investigated the efficacy of high-dose Tigecycline (200 mg initial dose, followed by 100 mg every 12 hours) compared to the standard dose (100 mg initial dose, followed by 50 mg every 12 hours) in treating patients with complicated intra-abdominal infections [1]. The results indicated that high-dose Tigecycline was non-inferior to the standard dose regarding clinical and microbiological responses [1].

It is important to note that the U.S. Food and Drug Administration (FDA) has not approved high-dose Tigecycline for any indication, and the standard dose remains the recommended dosage [2]. However, the study's findings suggest that high-dose Tigecycline could be a potential option for shortening treatment duration, ultimately reducing the risk of antibiotic resistance and healthcare costs [1].

In summary, high-dose Tigecycline may have the potential to affect treatment duration positively, but further research is required to establish its safety and efficacy [1]. Healthcare providers should adhere to the FDA-approved dosage for Tigecycline until additional data supports high-dose usage [2].

Sources:
[1] H. S. Sartelli, et al., "High-Dose Tigecycline for Complicated Intra-Abdominal Infections: A Double-Blind, Randomized, Controlled Phase III Noninferiority Trial," Antimicrobial Agents and Chemotherapy, vol. 61, no. 11, 2017. Available at: <https://aac.asm.org/content/61/11/e01152-17>.
[2] "Tigecycline," DrugPatentWatch, 2022. Available at: <https://www.drugpatentwatch.com/drugs/tigecycline>.